AVR Anteris Technologies

Anteris Technologies to Present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

Anteris Technologies to Present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

BRISBANE, Australia and EAGAN, Minn., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Anteris Technologies Ltd (ASX:AVR) (Anteris or the Company), a structural heart company advancing its novel DurAVR™ valve for aortic repair and replacement, today announced that Wayne Paterson, Chief Executive Officer, will present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Friday, February 19, 2021 at 10:30AM ET.

About Anteris Technologies Ltd (ASX:AVR)

Anteris Technologies Ltd is a structural heart company delivering clinically superior and durable solutions through better science and better design. Its focus is on developing next generation technologies that help healthcare professionals create life-changing outcomes for patients.

The Anteris DurAVR™ aortic replacement valve addresses the acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.

The proven benefits of its ADAPT® tissue technology, paired with DurAVR™’s unique 3D single-piece aortic valve design, has the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to the challenges facing heart surgeons today.

For more information:

Jason Wong

Blueprint Life Science Group

E:

P: (415) 375-3340 Ext. 4



Twitter: @AnterisTech

Facebook: /AnterisTech



EN
16/02/2021

Underlying

AVRAnteris Technologies

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Anteris Technologies

 PRESS RELEASE
Free
AVR Anteris Technol...

Anteris Announces Strategic Investment from Medtronic to Continue Adva...

Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises MINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: , ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced today it has completed a $90 million strategic investment from Medtronic, plc (Galway, Ireland) (NASDAQ: MDT) (Medtronic), the world’s largest medical technol...

January 22, 2026 1 EN
 PRESS RELEASE
Free
AVR Anteris Technol...

Anteris Technologies Global Corp. Announces Closing of $230 Million Pu...

Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock MINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: , ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the closing of its underwritten public offering (the “Offering”) of 40,000,000 shares of its common stock, including the exercise in full of the underwriters’ option to ...

January 22, 2026 1 EN
 PRESS RELEASE
Free
AVR Anteris Technol...

Anteris Technologies Global Corp. Announces Pricing of $200 Million Pu...

Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering MINNEAPOLIS and BRISBANE, Australia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: , ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the pricing of its public offering (the “Offering”) of 34,782,609 shares of its common stock (the “Shares”). The Shares are being sold at a public offering price of $5.75 per share. The...

January 21, 2026 1 EN
 PRESS RELEASE
Free
AVR Anteris Technol...

Anteris Technologies Global Corp. Announces Proposed $200 Million Publ...

Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic MINNEAPOLIS and BRISBANE, Australia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: , ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that it is offering to sell, subject to market and other conditions, $200 million of shares of its common stock through a proposed ...

January 20, 2026 1 EN
 PRESS RELEASE
Free
AVR Anteris Technol...

Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PC...

Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves MINNEAPOLIS and BRISBANE, Australia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) today released 30-day clinical outcomes for the DurAVR® THV in one hundred severe aortic stenosis patients with small aortic annuli (aortic annulus area 404 ± 37mm2). The DurAVR® THV demonstrated single digit mean gradients, large effective orifice areas (EOAs), no moderate or severe paravalvular leaks and no valve related mortality, with 97% freedom fr...

November 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch